Mediators of chronic heart failure: How drugs work

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1066-1074

  Terpening, C M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Chronic heart failure; Neurohormones

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; SPIRONOLACTONE; TUMOR NECROSIS FACTOR; VASOPEPTIDASE INHIBITOR;

DISEASE COURSE; HEART FAILURE; HEART FUNCTION; HORMONAL REGULATION; HUMAN; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VASCULARIZATION;

EID: 0034823243     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002800103500904     Document Type: Review

References (121)

1. Mechanisms and models in heart failure. A combinatorial approach
2. Hormones and hemodynamics in heart failure
3. Advances in the molecular mechanisms of heart failure
4. Evolution and pathophysiology of chronic systolic heart failure
5. The relationship of cardiovascular and renal hemodynamic function to sodium excretion in patients with severe heart disease but without edema
6. Endothelium as a therapeutic target in heart failure
7. Pathogenesis of renal sodium retention in congestive heart failure
8. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat
9. Osmotic and nonosmotic control of vasopressin release
10. Natriuretic peptides
11. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials
12. Angiotensin II and nitric oxide: A question of balance
13. Endothelial function as a determinant of vascular function and structure: A new therapeutic target
14. Kinins and endothelial control of vascular smooth muscle
15. Endothelial dysfunction: From physiology to therapy
16. Hypertension, heart failure, and endothelial function
17. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β
18. Angiotensin II and connective tissue: Homeostasis and reciprocal regulation
19. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells
20. Impact of endothelin-1 on vascular structure and function
21. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat
22. Arginine vasopressin-induced hypertrophy of cultured rat aortic smooth muscle cells
23. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cell in vitro
24. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature
25. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
26. Nitric oxide induces and inhibits apoptosis through different pathways
27. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system
28. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
29. The role of tumor necrosis factor in the pathophysiology of heart failure
30. Tumor necrosis factor-alpha provokes a hypertrophic response in adult cardiac myocytes
31. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells
32. Nitricoxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts
33. Role of endothelin-1 in myocardial failure
34. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure
35. β-blocker therapy: A standard of care for heart failure
36. Adrenergic effects on the biology of the adult mammalian cardiocyte
37. The role of TNF in cardiovascular disease
38. Overexpression of tumor necrosis factor-alpha activates the expression of multiple members of the apoptosis pathway in transgenic mice
39. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts
40. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness
41. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart
42. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrythmias
43. Ectopic arrythmia provoking action of aldosterone
44. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
45. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia
46. Consensus recommendations for the management of chronic heart failure
47. HFSA guidelines for the management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
48. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure
49. The effects of digoxin on mortality and morbidity in patients with heart failure
50. Captopril versus digoxin in mild-moderate heart failure: A crossover study
51. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multicenter Trial (DIMT)
52. Update on digoxin therapy in congestive heart failure
53. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors
54. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
55. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
56. A placebo-controlled trial of captopril in refractory chronic congestive heart failure
57. Placebo-controlled study of lisinopril in congestive heart failure: A multicentre study
58. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension
59. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure. Role of nitric oxide, prostanoids, oxidant stress, and bradykinin
60. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD electrocardiographic substudy
61. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
62. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
63. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure
64. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
65. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril
66. Chronic ACE inhibition by quinapril modulates central vasopressinergic system
67. Aldosterone escape during ACE inhibitor therapy in chronic heart failure
68. Interactions among ACE, kinins and NO
69. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
70. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
71. Inhibiting tissue angiotensin-converting enzyme. A pound of flesh without the blood?
72. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lungs, arteries, and veins
73. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
74. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
75. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study. N Engl J Med
76. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
77. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
78. Clinical effects of β-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials
79. β-adrenergic blocking agents in heart failure. Benefits of vasodilating and non-vasodilating agents according to patients' characteristics: A meta-analysis of clinical trials
80. β-adrenergic receptor blockade in chronic heart failure
81. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
82. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)
83. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade
84. β-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol
85. Effects of β blockers on neurohormonal activation in patients with congestive heart failure
86. The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischemic dilated cardiomyopathy
87. Chronic β-blocker treatment in patients with advanced heart failure. Effects on neurohormones
88. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure
89. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure
90. Differential effects of β-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
91. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
92. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
93. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure
94. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
95. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES)
96. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats
97. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
98. Interrupting the renin-angiotensin system: The role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension
99. Angiotensin II receptor blockers. Equal or preferred substitutes for ACE inhibitors?
100. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin receptor antagonists in congestive heart failure
101. Acute and chronic angiotensin-receptor antagonism reverses endothelial dysfunction in atherosclerosis
102. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy
103. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
104. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension
105. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - The Losartan Heart Failure Survival Study ELITE II
106. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
107. Role of tumor necrosis factor-alpha in the progression of heart failure. Therapeutic implications
108. Results of a targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
109. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. A randomized, double-blind, placebo-controlled clinical trial
110. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
111. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
112. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
113. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial
114. Plasma bradykinin in angio-oedema
115. Vasopeptidase inhibition and angio-oedema
116. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
117. Endothelin-1: A new target of therapeutic intervention for the treatment of heart failure
118. Short-term endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure